New alpha1-adrenoceptor antagonist, JTH-601, shows more than 10 times higher affinity for human prostates than arteries.

[1]  N. Ishida,et al.  KMD-3213, a novel α1A-adrenoceptor antagonist, potently inhibits the functional α1-adrenoceptor in human prostate , 1997 .

[2]  J. Hieble,et al.  Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. , 1997, The Journal of pharmacology and experimental therapeutics.

[3]  R. Graham,et al.  alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling. , 1996, Circulation research.

[4]  I. Muramatsu,et al.  Subtype selectivity of a new α1-adrenoceptor antagonist, JTH-601: comparison with prazosin , 1996 .

[5]  T. Stamey,et al.  RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. , 1996, Molecular pharmacology.

[6]  J. Hieble,et al.  Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. , 1995, Journal of medicinal chemistry.

[7]  R. Lefkowitz,et al.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. , 1995, Pharmacological reviews.

[8]  J. Regan,et al.  Vascular α-adrenoceptors: from the gene to the human , 1995 .

[9]  A. Hatano,et al.  Pharmacological evidence of distinct oci‐adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery , 1994, British journal of pharmacology.

[10]  H. Akino,et al.  Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies. , 1994, British journal of urology.

[11]  C. Strader,et al.  Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c. , 1994, Biochemical and biophysical research communications.

[12]  P. Molinoff,et al.  International Union of Pharmacology nomenclature of adrenoceptors. , 1994, Pharmacological reviews.

[13]  K. Minneman,et al.  Alpha 1-adrenergic receptor subtypes. , 1994, Annual review of pharmacology and toxicology.

[14]  D. McTavish,et al.  Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. , 1993, Drugs.

[15]  H. Lepor,et al.  The alpha‐adrenoceptor subtype mediating the tension of human prostatic smooth muscle , 1993, The Prostate.

[16]  I. Muramatsu,et al.  Three distinct binding sites for [3H]‐prazosin in the rat cerebral cortex , 1991, British journal of pharmacology.

[17]  K. Kawabe,et al.  Use of an α1-Blocker, YM617, in the Treatment of Benign Prostatic Hypertrophy , 1990 .

[18]  I. Muramatsu,et al.  Pharmacological subclassification of α1‐adrenoceptors in vascular smooth muscle , 1990 .

[19]  K. Minneman.  Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+. , 1988, Pharmacological reviews.

[20]  P. Abel,et al.  α1Adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle , 1987, Nature.

[21]  I. Creese,et al.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding. , 1986, Molecular pharmacology.

[22]  N. Flavahan,et al.  α1-Adrenoceptor subclassification in vascular smooth muscle , 1986 .

[23]  K. Andersson,et al.  Effects of prazosin in patients with benign prostatic obstruction. , 1983, The Journal of urology.

[24]  J. McGrath.  Evidence for more than one type of post-junctional α-Adrenoceptor , 1982 .

[25]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[26]  S. Meretyk,et al.  A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. , 1978, British journal of urology.

[27]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[28]  S. Raz,et al.  Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. , 1975, British journal of urology.

[29]  S. Raz,et al.  Pharmacological Receptors in the Prostate , 1973 .

[30]  H. Schild,et al.  SOME QUANTITATIVE USES OF DRUG ANTAGONISTS , 1997, British journal of pharmacology and chemotherapy.